Hims & Hers Health (HIMS) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$2.6B

Revenue (quarter)

$753.2M

Revenue growth (year over year)

+38.25%

Gross profit (trailing twelve months)

$1.8B

Gross margin

68.43%

Net income (trailing twelve months)

−$142.0M

Net income (quarter)

−$86.3M

Net income growth (year over year)

−303.01%

Net margin

−5.51%

Return on equity

−32.03%

EPS (trailing twelve months)

−$0.62

Book value per share

$1.39

P/E (trailing twelve months)

—

Price to book

20.21

Debt to assets

91.07%

Payout ratio

—

Dividend yield

—

Company profile

Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.

• Is Hims & Hers Health (HIMS) profitable?

  No. Hims & Hers Health reported a net loss of $142.0M over the trailing twelve months.

• How much revenue does Hims & Hers Health (HIMS) make?

  Hims & Hers Health generated $2.6B in revenue over the trailing twelve months, up 38.25% year over year.

• How do I buy stock in Hims & Hers Health (HIMS)?

  HIMS trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.